Dolphins acquire Darren Waller from Giants after former NFL star makes surprise return from retirement
Waller is coming out of retirement to play for the Miami Dolphins, who made a trade with the New York Giants to get him in the building before training camp, according to multiple reports Tuesday.
The Giants held Waller's rights after he announced his retirement after one season in New York in 2023. They received a 2026 sixth-round pick for Waller and a conditional 2027 seventh-round selection in the NFL Draft, according to ESPN.
Waller's return from retirement happened one day after the Dolphins sent their Pro Bowl tight end from 2024, Jonnu Smith, to the Pittsburgh Steelers in a deal involving Jalen Ramsey and Minkah Fitzpatrick.
Waller figures to be the starter, though he'll have to compete with Julian Hill and Pharaoh Brown for that role in training camp.
People close to Waller said he "missed football," according to ESPN, and he wanted to get back into the game if a team wanted him.
The 32-year-old was one of the best tight ends in the NFL with 2,341 receiving yards on 197 receptions with the Las Vegas Raiders in 2019 and 2020 combined. He had 12 touchdowns during that span.
The Raiders gave Waller a three-year extension worth $51 million, but he was traded to the Giants after the 2022 season.
Things didn't pan out in New York, where he caught 52 passes for 552 yards with just one touchdown in a lost 2023 campaign for Big Blue.
Waller eventually announced he was retiring after a health scare in November 2023.
In a YouTube video, Waller revealed he struggled to breathe and spent 3½ days in a hospital unable to stand up, use the bathroom or even feed himself. While he didn't disclose the diagnosis doctors gave him for those ailments, he said the "very scary situation" changed his mindset, and he decided to retire with a focus on his music career.
Waller has also been very public about his battles with addiction, most notably, a 2017 overdose that turned his life around for the better. He has since used his own experience with addiction and rehabilitation to help others.
With the Dolphins, Waller hopes to be a force on offense. He will be teaming up with Tua Tagovailoa, Tyreek Hill, Jaylen Waddle and other electric players on that side of the ball.
Waller will also reunite with his former Raiders tight ends coach, Frank Smith, who worked with him from 2018-20.
Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Guardians at Cubs Prediction: Odds, expert picks, starting pitchers, betting trends and stats for July 2
Its Wednesday, July 2 and the Guardians (40-43) are in Chicago to take on the Cubs (50-35). Tanner Bibee is slated to take the mound for Cleveland against Shota Imanaga for Chicago. The Cubs took the opener in the series by the score of 5-2 last night. Carson Kelly went 2-2 and drove in three runs to pace the offense and Matthew Boyd allowed five hits and two runs over seven innings to earn his eighth win of the season. Advertisement Lets dive into tonight's matchup and find a sweat or two. We've got all the info and analysis you need to know ahead of the game, including the latest info on the how to catch tipoff, odds, recent team performance, player stats, and of course, our predictions, picks & best bets for the game from our modeling tools and staff of experts. Follow Rotoworld Player News for the latest fantasy and betting player news and analysis all season long. Game details & how to watch Guardians at Cubs Date: Wednesday, July 2, 2025 Time: 8:05PM EST Site: Wrigley Field City: Chicago, IL Network/Streaming: CLEG, MARQ, MLBN Never miss a second of the action and stay up-to-date with all the latest team stats and player news. Check out our day-by-day MLB schedule page, along with detailed matchup pages that update live in-game with every out. Odds for the Guardians at the Cubs The latest odds as of Wednesday: Advertisement Moneyline: Guardians (+134), Cubs (-159) Spread: Cubs -1.5 Total: 9.0 runs Probable starting pitchers for Guardians at Cubs Pitching matchup for July 2, 2025: Tanner Bibee vs. Shota Imanaga Guardians: Tanner Bibee (4-8, 3.90 ERA) Last outing: 6/26 vs. Toronto - 6IP, 2ER, 3H, 0BB, 7Ks Cubs: Shota Imanaga (4-2, 2.54 ERA) Last outing: 6/26 at St. Louis - 5IP, 0ER, 1H, 1BB, 3Ks Rotoworld still has you covered with all the latest MLB player news for all 30 teams. Check out the feed page right here on NBC Sports for headlines, injuries and transactions where you can filter by league, team, positions and news type! Top betting trends & insights to know ahead of Guardians at Cubs The Cubs have won 4 of their last 5 home games against teams with losing records The Guardians' last 3 against the Cubs have stayed under the Total The Guardians have failed to cover the Run Line in 8 of their last 10 games Pete Crow-Armstrong snapped an 0-11 streak with a couple of hits last night If you're looking for more key trends and stats around the spread, moneyline and total for every single game on the schedule today, check out our MLB Top Trends tool on NBC Sports! Expert picks & predictions for tonight's game between the Guardians and the Cubs Rotoworld Best Bet Please bet responsibly. If you or someone you know has a gambling problem, call the National Gambling Helpline at 1-800-522-4700. Advertisement Our model calculates projections around each moneyline, spread and over/under bet for every game on the MLB calendar based on data points like past performance, player matchups, ballpark information and weather forecasts. Once the model is finished running, we put its projection next to the latest betting lines for the game to arrive at a relative confidence level for each wager. Here are the best bets our model is projecting for Wednesday's game between the Guardians and the Cubs: Moneyline: NBC Sports Bet is recommending a play on the Chicago Cubs on the Moneyline. Spread: NBC Sports Bet is leaning towards a play ATS on the Cleveland Guardians at +1.5. Total: NBC Sports Bet is leaning towards a play on the under on the Game Total of 9.0. Want even more MLB best bets and predictions from our expert staff & tools? Check out the Expert MLB Predictions page from NBC Advertisement Follow our experts on socials to keep up with all the latest content from the staff:
Yahoo
22 minutes ago
- Yahoo
HRT ‘can raise breast cancer risk' in younger women
Hormone replacement therapy can raise the risk of breast cancer in some younger women, a Lancet study suggests. An international team of researchers found the treatment was not linked to young onset breast cancer overall. But oestrogen plus progestin therapy appears to increase breast cancer risk by 10 per cent. Meanwhile, oestrogen hormone therapy use appeared to decrease breast cancer risk by 14 per cent. Hormone replacement therapy is a treatment used to help menopause symptoms. There are different types of HRT, which is used to treat menopause symptoms, available. They contain different hormones: some are oestrogen products; others contain progestogen and other types have both. These medicines can be taken or used in different ways and work by replacing the hormones oestrogen and progesterone, which can fall to lower levels as women approach the menopause. Most studies examining links between hormone therapy and breast cancer risk have been explored in older women. Previous work, which has focused on women who have already been through the menopause, suggest that oestrogen plus progestin hormone therapy is a risk factor for breast cancer. The researchers, led by academics from the National Institute of Environmental Health Sciences in the US, wanted to explore the risks among younger women on hormone therapy – who may take these drugs after gynaecological surgery or during perimenopause. The new meta-analysis published in the journal, Lancet Oncology, examined data drawn from previous studies of 459,476 women aged 16 to 54 years old. Some two per cent of this group (8,455) developed young-onset breast cancer, which means the disease was diagnosed before they were 55 years old. And 15 per cent of women involved in the study reported using hormone therapy, with oestrogen plus progestin hormone therapy and oestrogen being the most common types. 'Although the strength of these associations might vary by age at first use, duration of use, gynaecological surgery status, and other factors, unopposed oestrogen hormone therapy use appears to decrease breast cancer risk and oestrogen plus progestin therapy appears to increase breast cancer risk,' the authors wrote. 'The findings can be used to augment clinical recommendations for hormone therapy use in young women, for whom guidance was previously scarce.' Dr Kotryna Temcinaite, the head of research communications at Breast Cancer Now, said: 'These results are largely in line with what we already know about taking HRT for menopausal symptoms and its effects on breast cancer risk – for most people, the risk of developing breast cancer because of taking HRT is small and is outweighed by the benefits. 'Taking HRT is a very personal decision and, as such, it's vital that everyone has the information they need on the benefits and risks, discusses them with their GP or specialist team and is supported to make the choice that's right for them.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
22 minutes ago
- Yahoo
Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy
Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In the last twelve months, the biggest single sale by an insider was when the Executive VP & President of Commercial Health Benefits, Charles Kendrick, sold US$3.2m worth of shares at a price of US$432 per share. That means that an insider was selling shares at around the current price of US$396. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Elevance Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar). Over the last three months, we've seen significant insider selling at Elevance Health. Specifically, Executive VP & CFO Mark Kaye ditched US$1.9m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$103m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. An insider hasn't bought Elevance Health stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Elevance Health. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
